SB
RGLS

Samsara BioCapital’s Regulus Therapeutics RGLS Stock Holding History

Samsara BioCapital’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-90,441
Closed -$1.13M – 20
2019
Q2 		$1.13M Buy
+90,441
New +$1.04M 0.75% 17

Other funds holding RGLS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Samsara BioCapital's RGLS Position: Q3 2019 in Review

Samsara BioCapital sold out of Regulus Therapeutics (RGLS) in Q3 2019, closing a stake of 90,441 shares — an estimated $1.13M sold.

Samsara BioCapital first reported a position in RGLS in Q2 2019 and held it in 1 quarter. The position peaked at $1.13M in Q2 2019. 28 funds tracked by Wall St. Rank hold RGLS as of Q3 2019.

  • Samsara BioCapital reported no remaining Regulus Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Samsara BioCapital sold 90,441 Regulus Therapeutics shares in Q3 2019, an estimated $1.13M.
  • Samsara BioCapital first reported a position in Regulus Therapeutics in Q2 2019 and held it in 1 quarter.
  • Samsara BioCapital's Regulus Therapeutics position peaked at $1.13M in Q2 2019.
  • 28 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2019.

Based on Samsara BioCapital's 13F filing for Q3 2019, filed 14 Nov 2019.